Literature DB >> 12530970

Nature's TRAIL--on a path to cancer immunotherapy.

Mark J Smyth1, Kazuyoshi Takeda, Yoshihiro Hayakawa, Jacques J Peschon, Marcel R M van den Brink, Hideo Yagita.   

Abstract

The TNF-related apoptosis-inducing ligand (TRAIL) offers great promise as a cancer therapeutic. Initially, soluble recombinant versions of the TRAIL molecule have exhibited specific tumoricidal activity against a variety of tumors alone, or in combination with other cancer treatments, and much anticipation awaits the outcomes from early clinical trials. More recently, the natural role of TRAIL has been explored in tumor and allogeneic bone marrow transplantation models in the mouse. Strikingly, the TRAIL effector pathway appears a vital component of immunosurveillance of spontaneous or resident tumor cells by both T cells and NK cells, stimulating more hope that manipulating TRAIL activity is a natural path to improved cancer immunotherapy.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12530970     DOI： 10.1016/s1074-7613(02)00502-2

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


  80 in total

Review 1.  Anti-HER2 vaccines: new prospects for breast cancer therapy.

Authors:  Maha Zohra Ladjemi; William Jacot; Thierry Chardès; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Cancer Immunol Immunother       Date:  2010-06-08       Impact factor: 6.968

Review 2.  Hepatocyte death: a clear and present danger.

Authors:  Harmeet Malhi; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

Review 3.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

4.  TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells.

Authors:  Mitsuhiro Iyori; Tong Zhang; Haddon Pantel; Bethany A Gagne; Charles L Sentman
Journal:  J Immunol       Date:  2011-08-10       Impact factor: 5.422

5.  Adenovirus E3-6.7K protein is required in conjunction with the E3-RID protein complex for the internalization and degradation of TRAIL receptor 2.

Authors:  Drew L Lichtenstein; Konstantin Doronin; Karoly Toth; Mohan Kuppuswamy; William S M Wold; Ann E Tollefson
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells.

Authors:  Takeshi Azuma; Sheng Yao; Gefeng Zhu; Andrew S Flies; Sarah J Flies; Lieping Chen
Journal:  Blood       Date:  2008-01-25       Impact factor: 22.113

Review 7.  Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.

Authors:  Arnab Ghosh; Amanda M Holland; Marcel R M van den Brink
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Monocyte chemotactic protein-induced protein-1 enhances DR5 degradation and negatively regulates DR5 activation-induced apoptosis through its deubiquitinase function.

Authors:  You-Take Oh; Guoqing Qian; Jiusheng Deng; Shi-Yong Sun
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

9.  Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand.

Authors:  Paola Secchiero; Arianna Gonelli; Edvige Carnevale; Federica Corallini; Clara Rizzardi; Serena Zacchigna; Mauro Melato; Giorgio Zauli
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

10.  Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL.

Authors:  Nicole Clarke; Ana M Jimenez-Lara; Emilie Voltz; Hinrich Gronemeyer
Journal:  EMBO J       Date:  2004-07-08       Impact factor: 11.598
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.